Creating
Transformative
Therapies for Patients
with Significant
Unmet Need
About Us
ImmuneID is a precision therapeutics company developing transformational first-in-class and best-in-class medicines across a range of systemic autoimmune diseases, as well as cancer and neurological disorders.
Fueled by a novel, proprietary drug modality, under development in stealth mode, ImmuneID is competitively positioned to deliver life-changing therapies to patients with high unmet medical need.
Founded in late 2020 by Longwood Fund, ImmuneID is backed by top-tier biotechnology venture investors including Arch Venture Partners, Alta Partners, Pitango Healthtech Fund, Section 32, Alexandria Venture Investments, In-Q-Tel, Tekla Capital Management and Xfund.
Leadership
Our leadership team is composed of seasoned biotechnology leaders with a track record of success.
James S. Scibetta
Chief Executive Officer
Chief Business Officer
Jeremiah Degenhardt, PhD
Senior Vice President,
Preclinical & Translational Sciences
MBBS, PhD, FRACP
Consultant/Clinical Advisor
Shyam Unniraman, PhD
Senior Director,
Head of Preclinical Development
Christoph Westphal, PhD
ImmuneID Chair and Partner, Longwood Fund
Dan Janney
Managing Partner, Alta Partners
Ittai Harel
Managing Partner, Pitango Healthtech Fund
Steve Kafka, PhD
Managing Partner, Section 32
Peter Hutt
Senior Counsel, Covington & Burling LLP
James S. Scibetta
Director & Chief Executive Officer
Steve Elledge, PhD
Co-founder
David Walt, PhD
Scientific Advisor
INVESTORS
INVESTORS
Pipeline
ImmuneID is building an emerging pipeline focused on chronic diseases with enormous unmet medical need, with an initial focus on autoimmune diseases and oncology.
News & Media
Press Releases
ImmuneID Appoints Jessica Atkinson as Chief Business Officer
October 17, 2022
ImmuneID Announces Appointment of Pam Stetkiewicz, Ph.D., to Board of Directors
July 12, 2022
ImmuneID Appoints Jeremiah Degenhardt, Ph.D., as SVP Computational Biology
February 1, 2022
ImmuneID Appoints Veteran Biotech Executive James S. Scibetta as CEO
September 21, 2021
ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics
June 23, 2021
ImmuneID Appoints Annalisa D’Andrea as President and Chief Scientific Officer
April 5, 2021
ImmuneID Launches with $17M Financing to Profile and Modulate Immune Response at Unprecedented Scale and Resolution
February 17, 2021
Join Us
We are motivated by our core values of Collaboration, Inclusion, Commitment, Integrity, and Courage. This means we put the wellbeing of our team first, and we face tough problems head-on.
View Our Open Positions
Please review our open positions, if any, and apply now. We look forward to getting to know you!
- Scientist/Senior Scientist - Immunology
Equal Opportunity Employer
ImmuneID is proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability or any other status protected under federal, state or local law. All employment is decided on the basis of qualifications, merit and business need.
